The Gastrointestinal Market Outlook to 2012

Published by: Business Insights

Published: Oct. 1, 2007 - 189 Pages

Table of Contents

The Gastrointestinal Market Outlook to 2012

Executive Summary

Patient potential of GIT therapeutic area

Global market analysis

Pipeline analysis

Competitive landscape

Chapter 1 Patient potential of GIT therapeutic area

Summary

Introduction

Gastroesophageal reflux disorder

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Peptic ulcer disease

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Irritable bowel syndrome

Overview

Diagnosis, treatment and management

Epidemiology

Ulcerative colitis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Crohn’s disease

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Chapter 2 Global market analysis

Summary

Introduction

Market analysis by country

Licensing trends

Market analysis by drug class

Leading brand dynamics

Key events in the GIT market

Gastroesophageal reflux disorder and peptic ulcer disease

Leading brands of the GERD/PUD market

Proton pump inhibitor market analysis

Market dynamics

Key brands analysis

Histamine-2 receptor antagonist market analysis

Market dynamics

Key brands analysis

GERD/PUD sales forecasts to 2012

Irritable bowel syndrome

Competitive dynamics of IBS subclasses

Leading brands of the IBS market

GI sensorimotor modulators market analysis

Market dynamics

Key brands analysis

Antispasmodics/anticholinergics

Market dynamics

IBS sales forecasts to 2012

Inflammatory bowel disease: Crohn’s disease and ulcerative colitis

Competitive dynamics of Crohn’s disease and ulcerative colitis subclasses

Leading brands of IBD subclasses

Immunosuppressants market analysis

Market dynamics

Key brands analysis

Anti-rheumatic agents

Market dynamics

Key brands analysis

Intestinal anti-inflammatory agents

Market dynamics

Key brands analysis

IBD sales forecasts to 2012

Total GIT sales forecasts to 2012

Chapter 3 Pipeline analysis

Summary

Introduction

Key trends in R&D

Increasing penetration of generics in the GERD/PUD market will continue to

limit R&D investment

Continuing, yet uncertain focus on drug development in irritable bowel

syndrome

Emerging therapies for the management of inflammatory bowel disease

New mechanism of action

The GIT therapeutic area pipeline

Leading drugs in development

Profiles of key pipeline products

Phase II compounds

tetomilast (OPC-6535)

Alicaforsen (ISIS 2302)

OX-17

S-tenatoprazole-Na

Phase III compounds

Renzapride

Kremezin (AST-120)

Cimzia (certolizumab pegol)

TAK-390MR (dexlansoprazole)

Orencia (abatacept)

Drugs in registration

Ramosetron

Recently marketed drugs

Amitiza (lubiprostone)

Pipeline forecasts

Factors affecting forecasts

GIT pipeline forecasts

Chapter 4 Competitive landscape

Summary

Introduction

Market share

AstraZeneca

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Wyeth

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Abbott

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Johnson & Johnson

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Takeda

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Novartis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Astellas

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Eisai

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Altana

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Procter & Gamble

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline

Strategic analysis

Sales and promotions

Growth drivers

Growth constraints

Chapter 5 Appendix

IMS data

Licensing status

Index

Index

List of Figures

Figure 2.1: Global GIT market share by geography, 2006

Figure 2.2: Licensing status of global GIT sales, 2005-06 ($bn)

Figure 2.3: Competitive dynamics of the global GIT market by drug class, 2006

Figure 2.4: Competitive dynamics of the leading 10 brands in the global GIT market, 2005-06

Figure 2.5: Competitive dynamics of the global GERD/PUD market, 2005-06

Figure 2.6: Competitive dynamics of the leading 10 brands in the global GERD/PUD market, 2005-06

Figure 2.7: Competitive dynamics of the global IBS market, 2005-06

Figure 2.8: Competitive dynamics of the leading 10 brands in the global IBS market, 2005-06

Figure 2.9: Competitive dynamics of the global IBD market, 2005-06

Figure 2.10: Competitive dynamics of the leading 10 brands in the global IBD market, 2005-06

Figure 3.11: Prevailing R&D approaches

Figure 3.12: The GIT pipeline by indication and stage of development, 2006

Figure 3.13: Recently launched products and late-stage R&D compounds indicated for the GIT therapeutic area, 2006

Figure 4.14: Competitive dynamics of the leading players in the global GIT market, 2006

Figure 4.15: AstraZeneca’s GIT sales, 2006 ($m)

Figure 4.16: Wyeth’s GIT sales, 2006 ($m)

Figure 4.17: Abbott’s GIT sales, 2006 ($m)

Figure 4.18: J&J’s GIT sales, 2006 ($m)

Figure 4.19: Takeda’s GIT sales, 2006 ($m)

Figure 4.20: Novartis’ GIT sales, 2006 ($m)

Figure 4.21: Astellas’ GIT sales, 2006 ($m)

Figure 4.22: Eisai’s GIT sales, 2006 ($m)

Figure 4.23: Altana’s GIT sales, 2006 ($m)

Figure 4.24: P&G’s GIT sales, 2006 ($m)

List of Tables

Table 1.1: Estimated prevalence of major GIT indications in the seven major pharmaceutical markets, 2005

Table 1.2: Estimated prevalence of GERD across the seven major markets, 2006

Table 1.3: Forecast epidemiology of GERD across the seven major markets, 2006-12

Table 1.4: Estimated prevalence of PUD in the seven major pharmaceutical markets, 2006

Table 1.5: Forecast epidemiology of PUD across the seven major markets, 2006-12

Table 1.6: Estimated prevalence of IBS in the seven major pharmaceutical markets, 2006

Table 1.7: Forecast epidemiology of IBS across the seven major markets, 2006-12

Table 1.8: Estimated prevalence of ulcerative colitis in the seven major pharmaceutical markets, 2006

Table 1.9: Estimated epidemiology of UC across the seven major markets, 2006-12

Table 1.10: Estimated prevalence of Crohn’s disease in the seven major pharmaceutical markets, 2006

Table 1.11: Forecast prevalence of Crohn’s disease across the seven major markets, 2006-12

Table 2.12: Market size ($m) and growth (%) of drug classes within the global GIT market, 2002- 06

Table 2.13: Market size ($m) and growth (%) of leading brands in the global GIT market, 2005-06

Table 2.14: Market size ($m) and growth (%) of drug classes within the global GERD and PUD market, 2002-06

Table 2.15: Market size ($m) and growth (%) of leading GERD/PUD products, 2005-06

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.